Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients
Sunday, April 13, 2014 - 01:32
in Health & Medicine
Results from three Phase III clinical trials evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir 400mg and the NS5A inhibitor ledipasvir 90mg, with and without ribavirin, for the treatment of genotype 1 chronic hepatitis C virus infection have been presented.